Long non-coding RNA FTH1P3 facilitates uveal melanoma cell growth and invasion through miR-224-5p

Xiaoli Zheng¹‡*, Hongwei Tang¹‡, Xiaofeng Zhao², Yamei Sun³, Yanfang Jiang⁴, Yonghua Liu¹

¹ Department of Ophthalmology, Liaocheng People’s Hospital, Liaocheng, Shandong, China, ² Joint Laboratory for Translational Medicine, Liaocheng People’s Hospital, Liaocheng, Shandong, China, ³ Institute Pasteur of Shanghai Chinese Academy of Science, Shanghai, China, ⁴ Genetic Diagnosis Center, The First Hospital of Jilin University, Changchun, China

‡ Co-first authors
* xializheng1@yeah.net

Abstract

Growing evidences indicated that Long noncoding RNAs (IncRNAs) played important roles in tumor initiation and progression. However, the function and mechanism of IncRNA ferritin heavy chain 1 pseudogene 3 (FTH1P3) remain unknown in uveal melanoma. We showed that the expression level of FTH1P3 was upregulated in uveal melanoma cell lines and tissues. Elevated expression of FTH1P3 promoted uveal melanoma cell proliferation, cell cycle and migration. Moreover, we found that FTH1P3 was a direct target gene of miR-224-5p in uveal melanoma cell. Overexpression of FTH1P3 suppressed miR-224-5p expression and promoted the expression of Rac1 and Fizzled 5, which were the direct target genes of miR-224-5p. Furthermore, we showed that miR-224-5p expression level was downregulated in uveal melanoma cell lines and tissues. FTH1P3 expression was inversely correlated with the miR-224-5p expression in uveal melanoma tissues. Ectopic expression of miR-224-5p decreased uveal melanoma cell proliferation, cell cycle and migration. Elevated expression of FTH1P3 enhanced uveal melanoma cell proliferation and migration by inhibiting miR-224-5p expression. These results suggest that IncRNA FTH1P3 plays a crucial role in uveal melanoma. Investigation of the underlying mechanism may be a target for the treatment of uveal melanoma.

Introduction

Uveal melanoma is the most common primary intraocular malignancy cancers with a high mortality of about 50%[1–4]. Early metastasis is the most common cause for the high death rate of this disease[5–7]. Now, no effective treatment is available for patients with metastatic disease because the biology of uveal melanoma initiation and dissemination is unknown[8–10]. Despite several advances in chemotherapy, radiotherapy and surgery, the five year survival rate is still unsatisfactory [11–14]. Therefore, it is important to study the molecular event underlying progression and to find the novel therapeutic target of uveal melanoma.
Long noncoding RNAs (lncRNAs) are RNAs with more than 200 nucleotides in length with limited or no protein coding capacity.[15–19] It has been identified that lncRNAs play functional roles in many biological processes such as cell development, proliferation, metastasis, differentiation, invasion and migration.[20–24] Notably, a variety of lncRNAs were found to be deregulated in many tumors such as bladder cancer, glioma, lung cancer, gastric cancer and osteosarcoma.[25–29]. FTH1P3 (Ferritin heavy polypeptide 1 pseudogene 3) is one member of the ferritin heavy chain (FHC) gene family.[30]. FTH1P3 was found to be upregulated in oral squamous cell carcinoma (OSCC) [31]. Their data suggested that FTH1P3 promoted the OSCC cell progression through inhibiting the miR-224-5p expression and promoting the fizzled 5 expression. However, its function and expression in uveal melanoma are still unknown.

In this study, we tried to study the role of FTH1P3 in uveal melanoma. We found that FTH1P3 expression was overexpressed in uveal melanoma cell lines and tissues. Elevated expression of FTH1P3 increased uveal melanoma cell proliferation, cell cycle and migration.

**Materials and methods**

**Tissue samples, cell cultured and transfection**

Twenty-five uveal melanoma samples were obtained from uveal melanoma patients and normal uveal tissues were obtained from Beijing Tongren Eye Bank (Beijing, China). All cases provided written informed consent for our study and our study was approved by the Ethics Committee of The Liaocheng People’s Hospital. The cell lines (OCM-1A, MUM-2C, C918 and MUM-2B) and melanocyte cell line (D78) were collected from the Chinese Academy of Sciences (Beijing, China) and were cultured in DMEM medium. MiR-224-5p mimic and scramble mimic, pcDNA-FTH1P3 and control vectors were synthesized from Shanghai GenePharma (Shanghai, China). Cell transfection was done using Lipofectamine-2000 (Invitrogen, USA) according to the manufacturer’s protocol. FTH1P3 shRNA: top strand: 5’-CACCGCCAGCCCTCCGTCACTCTTCGAAGGGCTGGC-3’, and bottom strand: 5’-AAAAGCCAGCCCTCCGTCACTCTTCGAAGGGCTGGC-3’.

**RNA extraction and qPCR analysis**

Total RNA was isolated from cells or samples using the TRIZol reagent kit (Invitrogen, USA) following to manufacturer’s instructions. The expression of FTH1P3, miR-224-5p and Rac1 and fizzled 5 was determined by qRT-PCR with SYBR Green following to the manufacturer’s protocols. The primers were used as following: GAPDH, forward primers 5’-TCACCAGGGCTGCTTTTAAC-3’; reverse primers 5’-GACAAGCTTCCGTTCTAG-3’. FTH1P3, forward primers 5’-TCCATTATACCTGTGCGTGGC-3’; reverse primers 5’-GAAGGAAGATTGGCCACCT-3’. Rac1, forward primers 5’-GGCTAAGGAGATTGGTGCTGA-3’; reverse primers 5’-ACGAGGGCTGAGACATT-3’. miR-224-5p forward primer, 5’-CTGGTAGTGAAGTCACTA-3’. The relative expression of FTH1P3, miR-224-5p and Rac1 and fizzled 5 were measured with the \( \Delta \Delta CT \) method. U6 was used as the control for FTH1P3 and miR-224; GAPDH was performed as the control for Rac1 and fizzled 5.

**Cell proliferation, cell cycle and migration**

Cell proliferation was determined through using the CCK-8 (Cell Counting Assay Kit-8) (Dojindo, Japan) following to the manufacturer’s information. Cell proliferation was measured at the time of 0, 24, 48 and 72 hours and the absorbance at 450 nm was analyzed. For cell cycle, the cells fixed in the 70% ethanol and washed in PBS, then re-suspended in the PBS
containing RNase, Triton X-100 and propidium iodide (Sigma). The result was analyzed using a Flow Cytometer (BD Biosciences, CA). For cell migration, wound healing assays was performed. The cells were plated in the six-well plate and a wound was created by using the micropipette tip. Photograph was taken immediately and after 48 hours.

Western blot

Total protein extraction from cells or samples was lysed through using the protein extraction reagent RIPA (Beyotime, China). Equal amounts of protein extractions were resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes (Sigma-Aldrich, USA). After blocking with nonfat milk, membranes were incubated with primary antibodies (fizzled 5, Rac1 and GAPDH, Abcam). Signal was visualized by using ECL (Millipore). GAPDH was performed as the endogenous protein for normalization.

Statistical analysis

Student’s t-test and one-way ANOVA analysis were used to analyze the data by using the SPSS 18.0 software. Data were shown as mean ±SD. Difference was considered to be statistically significant at p<0.05.

Results

FTH1P3 expression level was overexpressed in uveal melanoma cell lines and samples

The expression level of FTH1P3 was upregulated in uveal melanoma cell lines (C918, MUM-2B, OCM-1A and MUM-2C) compared to that in melanocyte cell line (D78) (Fig 1A). In addition, we showed that FTH1P3 expression was higher in uveal melanoma samples than in the non-tumor samples (Fig 1B).

Elevated expression of FTH1P3 increased uveal melanoma cell proliferation and migration

To explore the role of FTH1P3 in uveal melanoma cell, we firstly enforced the FTH1P3 expression in MUM-2B cell using pcDNA-FTH1P3 (Fig 2A). Ectopic expression of FTH1P3
enhanced MUM-2B cell proliferation (Fig 2B). In addition, we found that elevated expression of FTH1P3 promoted the MUM-2B cell cycle (Fig 2C). Moreover, overexpression of FTH1P3 increased the MUM-2B cell migration (Fig 2D). The relative ratio of wound closure per field was shown.

**FTH1P3 was a direct target gene of miR-224-5p**

We used the miRDB (http://mirdb.org/cgi-bin/custom.cgi) to search the target gene of miR-224-5p. As shown in the Fig 3A, FTH1P3 might be a target gene of miR-224-5p. The expression level of miR-224-5p was upregulated in MUM-2B cell after treated with miR-224-5p mimic (Fig 3B). Overexpression of miR-224-5p decreased the luciferase activity of FTH1P3-WT, but not the luciferase activity of FTH1P3-Mut (Fig 3C). Elevated expression of miR-224-5p suppressed FTH1P3 expression in MUM-2B cell (Fig 3D).

**Overexpression of FTH1P3 decreased miR-224-5p expression**

Elevated expression of FTH1P3 suppressed miR-224-5p expression in the MUM-2B cell (Fig 4A). FTH1P3 overexpression enhanced Rac1 expression in the MUM-2B cell (Fig 4B). Ectopic expression of FTH1P3 promoted Fizzled 5 expression (Fig 4C). The protein expression of Rac1 (Fig 4C) and Fizzled 5 (Fig 4D) was also upregulated.
MiR-224-5p expression level was downregulated in uveal melanoma cell lines and samples and inversely correlated with FTH1P3

The expression level of miR-224-5p was downregulated in uveal melanoma cell lines (C918, MUM-2B, OCM-1A and MUM-2C) compared to the melanocyte cell line (D78) (Fig 5A). In addition, we showed that miR-224-5p expression was lower in uveal melanoma samples than in the non-tumor samples (Fig 5B). In addition, the expression of miR-224-5p in uveal melanoma tissues was inversely correlated with FTH1P3 expression (Fig 5C).

FTH1P3 enhanced uveal melanoma cell proliferation and migration by inhibiting the miR-224-5p expression

Ectopic expression of miR-224-5p suppressed MUM-2B cell proliferation (Fig 6A). Moreover, elevated expression of miR-224-5p inhibited MUM-2B cell cycle (Fig 6B). MiR-224-5p overexpression decreased MUM-2B cell migration and the relative ratio of wound closure per field was shown (Fig 6C). Next, we restored miR-224-5p expression through transfecting with miR-224-5p mimic into the FTH1P3 overexpressing-MUM-2B cells. The advantageous role of FTH1P3 on the MUM-2B cell proliferation was reversed by miR-224-5p overexpression (Fig 6D). Overexpression of miR-224-5p decreased the cell cycle in the FTH1P3 overexpressing-
MUM-2B cell (Fig 6E). Ectopic expression of miR-224-5p suppressed the cell migration in the FTH1P3 overexpressing-MUM-2B cell (Fig 6F).

**Discussion**

Increasing evidences showed lncRNAs played important roles in many tumor cellular processes such cell cycle, proliferation, survival, invasion and migration[32–37]. Until now, the mechanism and effect of lncRNAs are largely unclear in uveal melanoma tumorigenesis and
progression. LncRNA FTH1P3 is one member of lncRNAs located in the 2p23.3 with a length of 954 nucleotides[38]. Previous studies suggested that FTH1P3 acted as an oncogene in oral squamous cell carcinoma[31]. Zhang et al[31]. showed that FTH1P3 expression level was highly expressed in oral squamous cell carcinoma. Di et al[38]. reported that FTH1P3 transcript was found in many tissues and cell lines and the expression of FTH1P3 was positively regulated during cell differentiation process. In addition, Zhang et al[30]. demonstrated that FTH1P3 was upregulated in oral squamous cell carcinoma tissues. Overexpression of FTH1P3 enhanced oral squamous cell carcinoma cell colony formation and proliferation by regulating the expression of miR-224-5p and Fizzled 5. To our knowledge, there are no references about the role of FTH1P3 in uveal melanoma.

In the current study, we showed that FTH1P3 expression was overexpressed in uveal melanoma cell lines and tissues. Elevated expression of FTH1P3 increased uveal melanoma cell proliferation, cell cycle and migration. Moreover, we found that FTH1P3 was a direct target gene of miR-224-5p in uveal melanoma cell. Overexpression of FTH1P3 decreased miR-224-5p expression and promoted the expression of Rac1 and Fizzled 5, which were the direct target genes of miR-224-5p. Furthermore, we showed that miR-224-5p expression level was downregulated in uveal melanoma cell lines and tissues. The expression level of miR-224-5p was inversely correlated with FTH1P3 in uveal melanoma tissues. Ectopic expression of miR-224-5p decreased uveal melanoma cell proliferation, cell cycle and migration. Elevated expression of FTH1P3 enhanced the uveal melanoma cell proliferation and migration by inhibiting miR-224-5p expression.

Previous studies suggested that lncRNAs acted as sponges for miRNAs and abolished the suppressive effect of miRNAs on the targeted transcripts[39, 40]. Previous study showed that
FTH1P3 overexpression promoted oral squamous cell carcinoma progression through acting as a molecular sponge of miR-224-5p[31]. In line with this, we also showed that elevated expression of FTH1P3 suppressed the miR-224-5p expression in uveal melanoma cell. Moreover, we demonstrated that FTH1P3 overexpression promoted the expression of Rac1 and Fizzled 5, which were the target genes of miR-224-5p. Previous studies suggested that miR-224 played important roles in the tumor initiation and progression[41–43]. For example, Wang et al[44]. demonstrated that miR-224-3p expression was upregulated in HPV-infected tissues and cell lines. Overexpression of miR-224-3p inhibited the hrHPV-induced cervical cancer cell autophagy by targeting FAK family-interacting protein of 200 kDa (FIP200). Liu et al[45]. showed that miR-224 suppressed breast cancer cell migration and proliferation by inhibiting Fizzled 5 expression. Geng et al[46]. showed that miR-224 expression was decreased in osteosarcoma tissues and cell lines. Overexpression of miR-224 inhibited osteosarcoma cell migration, proliferation and invasion and contributed to the enhanced sensitivity of the osteosarcoma cells to cisplatin by regulating Rac1 expression. However, the function and mechanism of miR-224 in the uveal melanoma remain unknown. In this study, we demonstrated that the miR-224-5p expression level was downregulated in uveal melanoma cell lines and tissues. Interestingly, we showed that the expression of miR-224-5p was inversely correlated with FTH1P3 in uveal melanoma tissues. Moreover, ectopic expression of miR-224-5p suppressed uveal melanoma cell proliferation, cell cycle and migration. In addition, ectopic expression of FTH1P3 promoted uveal melanoma cell proliferation, cell cycle and migration through inhibiting miR-224-5p expression.

In conclusion, we demonstrated that lncRNA FTH1P3 was commonly up-regulated in uveal melanoma cell lines and tissues and acted as an oncogene in uveal melanoma progression by inhibiting miR-224-5p expression. These results suggest that lncRNA FTH1P3 plays a crucial role in uveal melanoma and investigation of the underlying mechanism may be a target for the treatment of uveal melanoma.

Author Contributions

Conceptualization: Hongwei Tang.

Data curation: Xiaoli Zheng, Yamei Sun.

Investigation: Hongwei Tang, Xiaofeng Zhao.

Writing – original draft: Xiaoli Zheng, Hongwei Tang.

Writing – review & editing: Xiaoli Zheng, Yanfang Jiang, Yonghua Liu.

References

1. Sato T, Han F, Yamamoto A. The biology and management of uveal melanoma. Current oncology reports. 2008; 10(5):431–8. Epub 2008/08/19. PMID: 18706273.

2. Topcu-Yilmaz P, Kiratli H, Saglam A, Soylermezoglu F, Hascelik G. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma research. 2010; 20(2):126–32. Epub 2010/01/12. https://doi.org/10.1097/CMR.0b013e328335a916 PMID: 20061986.

3. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118(9):1881–5. Epub 2011/06/28. https://doi.org/10.1016/j.ophtha.2011.01.040 PMID: 21704381.

4. Yonekawa Y, Kim IK. Epidemiology and management of uveal melanoma. Hematology/oncology clinics of North America. 2012; 26(6):1169–84. Epub 2012/11/03. https://doi.org/10.1016/j.hoc.2012.08.004 PMID: 23116575.
5. Pereira PR, Odashiro AN, Lim LA, Miyamoto C, Blanco PL, Odashiro M, et al. Current and emerging treatment options for uveal melanoma. Clin Ophthalmol. 2013; 7:1669–82. Epub 2013/09/05. https://doi.org/10.2147/OPHT.2013.582863; PubMed Central PMCID: PMC3755706.

6. Patel SP. Latest developments in the biology and management of uveal melanoma. Current oncology reports. 2013; 15(6):509–16. Epub 2013/10/15. https://doi.org/10.1007/s11912-013-0348-9; PubMed Central PMCID: 24122445.

7. Yousef YA, Alkilani M. Characterization, treatment, and outcome of uveal melanoma in the first two years of life. Hematol Oncol Stem Cell Ther. 2014. Epub 2014/10/11. https://doi.org/10.1016/j.hem onc.2014.09.004; PubMed Central PMCID: 25300563.

8. Liu N, Sun Q, Chen J, Li J, Zeng Y, Zhai S, et al. MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-kappaB1 pathway. Oncology reports. 2012; 28(3):961–8. Epub 2012/07/25. https://doi.org/10.3892/or.2012.1905; PubMed Central PMCID: 22825752.

9. Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R, Schwartz GK. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Molecular cancer therapeutics. 2013; 12(12):2817–26. Epub 2013/10/22. https://doi.org/10.1158/1535-7163.MCT-13-0499; PubMed Central PMCID: 24140933.

10. Economou MA. Uveal melanoma and macular degeneration: molecular biology and potential therapeutic applications. Acta ophthalmologica. 2008; 86(8):930–1. Epub 2008/12/18. https://doi.org/10.1111/j.1755-3768.2008.01188.x; PubMed Central PMCID: 19086934.

11. Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study. Current eye research. 2007; 32(3):281–90. Epub 2007/04/25. https://doi.org/10.1080/02713680601161220; PMID: 17453948.

12. Sun L, Bian G, Meng Z, Dang G, Shi D, Mi S. MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression. PloS one. 2015; 10(5):e0124428. Epub 2015/05/12. https://doi.org/10.1371/journal.pone.0124428; PubMed Central PMCID: PMC4427317.

13. Sun L, Wang Q, Gao X, Shi D, Mi S, Han Q. MicroRNA-454 functions as an oncogene by regulating PTEN in uveal melanoma. FEBS letters. 2015; 589(19 Pt B):2791–6. Epub 2015/08/25. https://doi.org/10.1016/j.febslet.2015.08.007; PubMed Central PMCID: 26296312.

14. Yan D, Dong XD, Chen X, Yao S, Wang L, Wang J, et al. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PloS one. 2012; 7(7):e40967. Epub 2012/08/01. https://doi.org/10.1371/journal.pone.0040967; PubMed Central PMCID: PMC3407171.

15. Liu CB, Lin JJ. Long noncoding RNA FTH1P3 facilitates uveal melanoma cell growth and invasion through miR-224-5p. FEBS letters. 2015; 589(19 Pt B):2791–6. Epub 2015/08/25. https://doi.org/10.1016/j.febslet.2015.08.007; PubMed Central PMCID: 26296312.

16. Li P, Xue WJ, Feng Y, Mao QS. Long non-coding RNA CASC2 suppresses the proliferation of gastric cancer cells by regulating the MAPK signaling pathway. American journal of translational research. 2016; 8(8):3522–9. PMID: 27648142

17. Wang LN, Lin YN, Meng H, Liu CY, Xue J, Zhang Q, et al. Long non-coding RNA LOC283070 mediates the transition of LNCaP cells into androgen-independent cells possibly via CAMK1D. American journal of translational research. 2016; 8(12):2817–26. Epub 2016/10/01. https://doi.org/10.2147/OPTH.S28863; PubMed Central PMCID: PMC4434820.
Molecular cancer therapeutics. 2015; 14(1):268–77. https://doi.org/10.1158/1535-7163.MCT-14-0492 PMID: 25504755

24. Ma L, Zhou YJ, Luo XJ, Gao H, Deng XB, Jiang YJ. Long non-coding RNA XIST promotes cell growth and invasion through regulating miR-497/MACC1 axis in gastric cancer. Oncotarget. 2017; 8(3):4125–35. https://doi.org/10.18632/oncotarget.13670 PMID: 27911852

25. He A, Liu Y, Chen Z, Li J, Chen M, Liu L, et al. Over-expression of long noncoding RNA BANCR inhibits malignant phenotypes of human bladder cancer. Journal of experimental & clinical cancer research: CR. 2016; 35(1):125. Epub 2016/08/16. https://doi.org/10.1186/s13046-016-0397-9 PMID: 27514530; PubMed Central PMCID: PMC4981950.

26. Li C, Lei BX, Huang SB, Zheng MG, Liu ZH, Li ZJ, et al. H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma. American journal of translational research. 2015; 7(10):1747–64. PMID: 26692922

27. Yang F, Xue X, Bi J, Zheng L, Zhi K, Gu Y, et al. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. Journal of cancer research and clinical oncology. 2013; 139(3):437–45. Epub 2012/11/13. https://doi.org/10.1007/s00432-012-1324-x PMID: 23143645.

28. Tian ZZ, Guo XJ, Zhao YM, Fang Y. Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma. International journal of clinical and experimental pathology. 2015; 8(11):15138–42. Epub 2016/01/30. PMID: 26823857; PubMed Central PMCID: PMC4713643.

29. Sun CC, Li SJ, Li G, Hua RX, Zhou XH, Li DJ. Long Intergenic Noncoding RNA 00511 Acts as an Oncogene in Non-small Cell Lung Cancer. Scientific reports. 2015; 5:15811–7. https://doi.org/10.1038/srep15811 PMID: 26726270

30. Zhang CZ. Long non-coding RNA FTH1P3 facilitates oral squamous cell carcinoma progression by acting as a molecular sponge of miR-224-5p to modulate fuzilled 5 expression. Gene. 2017; 607:47–55. https://doi.org/10.1016/j.gene.2017.01.009 PMID: 28093311

31. Wang J, Sun L, Chen X, Li P, Cai Q, Yu B, et al. MALAT1 promotes cell proliferation in gastric cancer by recruiting SF2/ASF. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2014; 68(5):557–64. Epub 2014/05/27. https://doi.org/10.1016/j.biopha.2014.04.007 PMID: 24857712.

32. Sun CC, Li SJ, Li G, Hua RX, Zhou XH, Li DJ. Long Intergenic Noncoding RNA 00511 Acts as an Oncogene in Non-small Cell Lung Cancer by Binding to EZH2 and Suppressing p57. Mol Ther-Nucl Acids. 2016; 5. https://doi.org/10.1038/mtna.2016.9 PMID: 27677712

33. Zhou X, Liu S, Cai G, Kong L, Zhang T, Ren Y, et al. Long Non Coding RNA MALAT1 Promotes Tumor Growth and Metastasis by Inducing Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma. Scientific reports. 2015; 5:15972. Epub 2015/11/03. https://doi.org/10.1038/srep15972 PMID: 26726270

34. Zhang CZ. Long non-coding RNA FTH1P3 facilitates oral squamous cell carcinoma progression by acting as a molecular sponge of miR-224-5p to modulate fuzilled 5 expression. Gene. 2017; 607:47–55. https://doi.org/10.1016/j.gene.2017.01.009 PMID: 28093311

35. Qiao HP, Gao WS, Huo JX, Yang ZS. Long non-coding RNA GAS5 functions as a tumor suppressor in renal cell carcinoma. Asian Pacific journal of cancer prevention: APJCP. 2013; 14(2):1077–82. Epub 2013/04/30. PMID: 23621190.

36. Fang J, Sun CC, Gong C. Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression. Biochemical and biophysical research communications. 2016; 478(2):811–7. https://doi.org/10.1016/j.bbrc.2016.08.030 PMID: 27501756

37. Song P, Yin SC. Long non-coding RNA EWSAT1 promotes human nasopharyngeal carcinoma cell growth in vitro by targeting miR-326/-330-5p. Aging-Us. 2016; 8(11):2948–60. https://doi.org/10.18632/aging.101103 PMID: 27816050

38. Sun CC, Li SJ, Li DJ. Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1. Oncotarget. 2016; 7(24):35960–78. https://doi.org/10.18632/oncotarget.8482 PMID: 27166267

39. Di Sanzo M, Aversa I, Santamaria G, Gagliardi M, Panebianco M, Biamonte F, et al. FTH1P3, a Novel H-Ferritin Pseudo gene Transcriptionally Active, Is Ubiquitously Expressed and Regulated during Cell Differentiation. PloS one. 2016; 11(3). https://doi.org/10.1371/journal.pone.0151359 PMID: 26982978

40. Deng L, Yang SB, Xu FF, Zhang JH. Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge. Journal of experimental & clinical cancer research: CR. 2015; 34:18. Epub 2015/04/18. https://doi.org/10.1186/s13046-015-0136-7 PMID: 25884472; PubMed Central PMCID: PMC4339002.

41. Li JQ, Hu SY, Wang ZY, Lin J, Jian S, Dong YC, et al. Long non-coding RNA MEG3 inhibits microRNA-125a-5p expression and induces immune imbalance of Treg/Th17 in immune thymobectomy purpura. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016; 83:905–11. Epub 2016/08/16. https://doi.org/10.1016/j.biopha.2016.07.057 PMID: 27522004.
41. Xia MM, Wei JB, Tong KH. MiR-224 promotes proliferation and migration of gastric cancer cells through targeting PAK4. Die Pharmazie. 2016; 71(8):460–4. https://doi.org/10.1691/ph.2016.6580
42. Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, et al. The clinical and biological significance of MiR-224 expression in colorectal cancer metastases. Gut. 2016; 65(6):977–89. https://doi.org/10.1136/gutjnl-2015-309372 PMID: 25804630
43. Adamopoulos PG, Kontos CK, Rapti SM, Papadopoulos IN, Scorilas A. miR-224 overexpression is a strong and independent prognosticator of short-term relapse and poor overall survival in colorectal adenocarcinoma. International journal of oncology. 2015; 46(2):849–59. https://doi.org/10.3892/ijo.2014.2775 PMID: 25420464
44. Wang F, Shan S, Li YM, Zhu ED, Yin LR, Sun B. miR-224-3p inhibits autophagy in cervical cancer cells by targeting FIP200. Scientific reports. 2016; 6. https://doi.org/10.1038/srep33229 PMID: 27615604
45. Liu F, Liu Y, Shen JL, Zhang GQ, Han JG. MicroRNA-224 inhibits proliferation and migration of breast cancer cells by down-regulating fizzled 5 expression. Oncotarget. 2016; 7(31):49130–42. https://doi.org/10.18632/oncotarget.9734 PMID: 27323393
46. Geng S, Gu LN, Ju F, Zhang HP, Wang YW, Tang H, et al. MicroRNA-224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1. Journal of cellular and molecular medicine. 2016; 20(9):1611–9. https://doi.org/10.1111/jcmm.12852 PMID: 27222381